AU2863895A - Combination therapy for hiv infection - Google Patents
Combination therapy for hiv infectionInfo
- Publication number
- AU2863895A AU2863895A AU28638/95A AU2863895A AU2863895A AU 2863895 A AU2863895 A AU 2863895A AU 28638/95 A AU28638/95 A AU 28638/95A AU 2863895 A AU2863895 A AU 2863895A AU 2863895 A AU2863895 A AU 2863895A
- Authority
- AU
- Australia
- Prior art keywords
- combination
- hiv
- compound
- reverse transcriptase
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26708594A | 1994-06-27 | 1994-06-27 | |
US267085 | 1994-06-27 | ||
PCT/US1995/007690 WO1996000068A2 (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2863895A true AU2863895A (en) | 1996-01-19 |
Family
ID=23017251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU28638/95A Withdrawn AU2863895A (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0767664A2 (fi) |
JP (1) | JPH10503178A (fi) |
AU (1) | AU2863895A (fi) |
CA (1) | CA2193221A1 (fi) |
CZ (1) | CZ375196A3 (fi) |
FI (1) | FI965196A0 (fi) |
HU (1) | HUT76546A (fi) |
IL (1) | IL114208A0 (fi) |
MX (1) | MX9700036A (fi) |
NO (1) | NO965591L (fi) |
PL (1) | PL317876A1 (fi) |
SK (1) | SK163996A3 (fi) |
WO (1) | WO1996000068A2 (fi) |
ZA (1) | ZA955269B (fi) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
SK285240B6 (sk) | 1999-09-24 | 2006-09-07 | Janssen Pharmaceutica N. V. | Antivírusové prostriedky |
EP3353527B1 (en) | 2015-09-23 | 2022-12-28 | Malvern Panalytical Limited | Particle characterisation |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/xx unknown
- 1995-06-23 CA CA002193221A patent/CA2193221A1/en not_active Abandoned
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/cs unknown
- 1995-06-23 JP JP8503245A patent/JPH10503178A/ja active Pending
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/en not_active Application Discontinuation
- 1995-06-23 HU HU9603567A patent/HUT76546A/hu unknown
- 1995-06-23 PL PL95317876A patent/PL317876A1/xx unknown
- 1995-06-23 SK SK1639-96A patent/SK163996A3/sk unknown
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-23 EP EP95923935A patent/EP0767664A2/en not_active Withdrawn
- 1995-06-23 MX MX9700036A patent/MX9700036A/es unknown
- 1995-06-26 ZA ZA955269A patent/ZA955269B/xx unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196A0/fi not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996000068A2 (en) | 1996-01-04 |
NO965591D0 (no) | 1996-12-27 |
FI965196A (fi) | 1996-12-23 |
NO965591L (no) | 1996-12-27 |
PL317876A1 (en) | 1997-04-28 |
JPH10503178A (ja) | 1998-03-24 |
CZ375196A3 (en) | 1997-07-16 |
FI965196A0 (fi) | 1996-12-23 |
HU9603567D0 (en) | 1997-02-28 |
SK163996A3 (en) | 1997-08-06 |
HUT76546A (en) | 1997-09-29 |
EP0767664A2 (en) | 1997-04-16 |
CA2193221A1 (en) | 1996-01-04 |
IL114208A0 (en) | 1995-10-31 |
ZA955269B (en) | 1996-02-02 |
WO1996000068A3 (en) | 1996-02-22 |
MX9700036A (es) | 1997-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5578597A (en) | Combination therapy for HIV infection | |
US6689761B1 (en) | Combination therapy for HIV infection | |
US6180634B1 (en) | Combination therapy for the treatment of AIDS | |
AU2863895A (en) | Combination therapy for hiv infection | |
EP1044000B1 (en) | Combination therapy for the treatment of aids | |
CA2197207C (en) | Hiv protease inhibitor combination | |
RU2194506C2 (ru) | Сочетание ингибиторов вич-протеазы | |
CZ20001752A3 (cs) | Farmaceutické prostředky obsahující kombinaci pro léčbu AIDS |